Hichip Pharmaceuticals: Final analysis results of the HP515 Phase IIa clinical trial

HuiChuang Pharmaceutical announced that the final analysis of the Phase IIa clinical trial of the innovative drug HP515, which is intended for the treatment of metabolic-related fatty liver disease, has achieved the primary and key secondary endpoints. The main results showed that the average LFC reduction in the various dosage groups of HP515 tablets taken orally once daily for 12 weeks was over 50%, while the placebo group only decreased by 3.5%. The differences between the drug groups and the placebo group were statistically significant.